Dr. Lazarev is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1184 5th Ave
New York, NY 10029Phone+1 646-872-9186Fax+1 212-410-7194
Summary
- Dr. Stanislav (Stas) Lazarev, MD, is an Assistant Professor and the Associate Program Director of the Radiation Oncology Residency Program at the Icahn School of Medicine at Mount Sinai in New York City. He provides patient care at both Mount Sinai Hospital and the New York Proton Center.
Dr. Lazarev specializes in the personalized treatment of central nervous system (CNS) tumors, including primary and metastatic brain and spinal cord tumors in both children and adults, leptomeningeal disease (LMD), pediatric tumors, and the re-irradiation of CNS, thoracic, and hepatobiliary tumors. His other major focus is the radiation treatment of primary thoracic and hepatobiliary tumors using proton beam therapy. His clinical expertise includes proton craniospinal irradiation (CSI) for LMD, proton re-irradiation, proton radiotherapy for pediatric cancers, and low-dose re-irradiation for recurrent pediatric diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma, H3 K27-altered WHO Grade 4.
In recognition of his dedication to compassionate and effective communication, Dr. Lazarev was honored with the Cullman Family Award for Excellence in Provider Communication in 2024. Dr. Lazarev was among 89 Mount Sinai providers who ranked in the top 5% nationally in provider communication, as measured by the Press Ganey 2023 patient experience surveys.
Dr. Lazarev’s commitment to education has also been recognized with the Association of Residents in Radiation Oncology (ARRO) Educator of the Year Award in both 2022 and 2024.
Dr. Lazarev’s work reflects his dedication to advancing cancer care across all settings, from local clinical practice to national and international initiatives, ensuring that his expertise benefits diverse patient populations while driving innovations in radiation oncology.
Education & Training
- Icahn School of Medicine at Mount SinaiResidency, Radiation Oncology, 2015 - 2019
- University of Vermont College of MedicineClass of 2014
- University of California, BerkeleyB.A., Biochemistry and Molecular Biology, Magna Cum Laude, 2009
- Pyatigorsk State Linguistic UniversityB.A. Candidate, Theory and Practice of Translation and Interpretation (Russian/English/Spanish) , 2004
- Instituto CervantesDiploma of Spanish as a Second Language (DELE), 2003
Certifications & Licensure
- NY State Medical License 2019 - 2026
- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- Best of ASTRO Abstract 2017
- Summer Undergraduate Research Fellowship Scholarship Yale University, 2008
- Alumni Leadership Award Scholarship University of California, Berkeley, 2007-2008
- Join now to see all
Publications & Presentations
PubMed
- Vorasidenib: a new hope or a false promise for patients with low-grade glioma?Stanislav Lazarev, Kunal K Sindhu
Nature Reviews. Clinical Oncology. 2024-12-01 - Reirradiation With Proton Therapy for Recurrent Malignancies of the Esophagus and Gastroesophageal Junction: Results of the Proton Collaborative Group Multi-Institutio...Alexandra Hotca, Kunal K Sindhu, Eric J Lehrer, William F Hartsell, Carlos Vargas
Advances in Radiation Oncology. 2024-05-01 - 4 citationsRadiation Therapy in the Management of Leptomeningeal Disease From Solid Tumors.Andrew B Barbour, Rupesh Kotecha, Stanislav Lazarev, Joshua D Palmer, Timothy Robinson
Advances in Radiation Oncology. 2024-02-01
Journal Articles
- Premature Discontinuation of Curative Radiotherapy: Insights from Head and Neck IrradiationLazarev S, Gupta V, Ghiassi-Nejad Z, Miles B, Scarborough B, Misiukiewicz KJ, Reckson B, Sheu R, Bakst R, Advances Radiat Oncol
- Low-Dose-Rate Brachytherapy for Prostate Cancer: Outcomes Beyond 10-years of Follow-UpLazarev S, Thompson M, Stone N, Stock R, BJU Int, 1/1/2018
- Premature Discontinuation of Curative Radiotherapy: Insights from Head and Neck IrradiationLazarev S, Gupta V, Ghiassi-Nejad Z, Miles B, Scarborough B, Misiukiewicz KJ, Reckson B, Sheu R, Bakst R, Advances Radiat Oncol, 1/1/2018
- Join now to see all
Abstracts/Posters
- Discontinuation of Curative Head and Neck Irradiation: Etiologies and Outcomes.Lazarev S, Ghiassi-Nejad Z, Gupta V, Miles B, Scarborough B, Misiukiewicz K, Reckson B, Sheu R, Bakst R, Multidisciplinary Head And Neck Cancers Symposium, Scottsdale, AZ, 1/1/2018
- Premature Discontinuation of Curative Radiotherapy: Insights from Head and Neck Irradiation.Lazarev S, Gupta V, Ghiassi-Nejad Z, Scarborough B, Reckson B, Sheu R, Bakst R, 59th American Society for Radiation Oncology Annual Meeting, San Diego, CA, 1/1/2017
- Clinical Outcomes after Premature Discontinuation of Curative Head and Neck Irradiation.Lazarev S, Ghiassi-Nejad Z, Gupta V, Misiukiewicz K, Miles B, Sheu R, Bakst R, 59th American Society for Radiation Oncology Annual Meeting, San Diego, CA, 1/1/2017
- Join now to see all
Lectures
- Oncological Emergencies: What is the Role of Radiation Therapy?Oakland, CA - 1/5/2018
- Low-dose-rate Brachytherapy as Monotherapy for High-Risk Prostate Cancer: 15-year Outcomes Data.Orlando, FL - 1/1/2018
- "Bath Salts": The New Designer Drug of AbuseBurlington, VT - 1/1/2012
- Join now to see all
Other
- LDR Brachytherapy for Prostate Cancer Offers Excellent SurvivalLazarev S, Renal & Urology News
1/1/2018 - Optimizing treatment positioning to achieve better heart sparing in a left-sided, whole-breast irradiation case unfit for deep-inspiration breath-hold treatmentDumane VA, Lazarev S, Sheu RD, Lo YC, Green S, Appl Rad Oncol.
http://appliedradiationoncology.com/articles/optimizing-treatment-positioning-to-achieve-better-heart-sparing-in-a-left-sided-whole-breast-irradiation
Appl Rad Oncol. 2016;5(2):22-26 - 5/2016
Press Mentions
- Vorasidenib for Certain IDH-Mutant Gliomas: Is It Worth It?December 2nd, 2024
- Mount Sinai Researchers Publish Critical Examination of New Brain Tumor DrugSeptember 23rd, 2024
- Suny Downstate Hematology Oncology FellowshipJune 11th, 2021
Professional Memberships
- Member
- Member
- Paediatric Radiation Oncology Society, PROSMember
Other Languages
- Catalan, Portuguese, Russian, Spanish, French, Hebrew
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: